Susquehanna International Group
DCOY

Susquehanna International Group’s Decoy Therapeutics DCOY Stock Holding History

Susquehanna International Group’s Portfolio DCOY Stock Details DCOY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Hold
0
– -$82K – 10341
2018
Q1 		– Hold
0
– – – 8776
2017
Q1 		– Hold
0
– -$53K – 9866
2016
Q4 		– Hold
0
– – – 9279
2016
Q3 		– Hold
0
– – – 6187

Other funds holding DCOY

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
HKAM
Horizon Kinetics Asset Management New York $9.23B AUM 27.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Susquehanna International Group's DCOY Position: Q1 2024 in Review

Susquehanna International Group sold out of Decoy Therapeutics (DCOY) in Q1 2024, closing a stake of 21 shares — an estimated $19.5K sold.

Susquehanna International Group first reported a position in DCOY in Q4 2020 and held it in 4 quarters. The position peaked at $30K in Q4 2020. 7 funds tracked by Wall St. Rank hold DCOY as of Q1 2024.

  • Susquehanna International Group reported no remaining Decoy Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Susquehanna International Group sold 21 Decoy Therapeutics shares in Q1 2024, an estimated $19.5K.
  • Susquehanna International Group first reported a position in Decoy Therapeutics in Q4 2020 and held it in 4 quarters.
  • Susquehanna International Group's Decoy Therapeutics position peaked at $30K in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Decoy Therapeutics as of Q1 2024.

Based on Susquehanna International Group's 13F filing for Q1 2024, filed 7 May 2024.